PT - JOURNAL ARTICLE AU - Frida Fart AU - Samira Salihović AU - Aidan McGlinchey AU - Melanie G. Gareau AU - Matej Orešič AU - Jonas Halfvarson AU - Tuulia Hyötyläinen AU - Ida Schoultz TI - Perfluoroalkyl Substances are increased in patients with Late-Onset Ulcerative colitis and induce Intestinal Barrier defects <em>ex vivo</em> in Murine Intestinal tissue AID - 10.1101/2020.06.03.20120550 DP - 2021 Jan 01 TA - medRxiv PG - 2020.06.03.20120550 4099 - http://medrxiv.org/content/early/2021/04/02/2020.06.03.20120550.short 4100 - http://medrxiv.org/content/early/2021/04/02/2020.06.03.20120550.full AB - Background Environmental factors are strongly implicated in late-onset of inflammatory bowel disease. Here, we investigate whether high exposure to perfluoroalkyl substances correlates with (1) late-onset inflammatory bowel disease, and (2) disturbances of the bile acid pool. We further explore the effect of the specific perfluoroalkyl substance perfluoronoctanoic acid on intestinal barrier function in murine tissue.Methods Serum levels of perfluoroalkyl substances and bile acids were assessed by ultra-performance liquid chromatography coupled to a triple-quadrupole mass spectrometer in matched samples from patients with ulcerative colitis (n=20) and Crohn’s disease (n=20) diagnosed at the age of ≥55 years. Age and sex-matched blood donors (n=20), were used as healthy controls. Ex vivo Ussing chamber experiments were performed to assess the effect of perfluoronoctanoic acid on ileal and colonic murine tissue (n=9).Results The total amount of perfluoroalkyl substances was significantly increased in patients with ulcerative colitis compared to healthy controls and patients with Crohn’s disease (p&lt;0.05). Ex vivo exposure to perfluoronoctanoic acid induced a significanlty altered ileal and colonic barrier function. The distribution of bile acids, as well as the correlation pattern between (1) perfluoroalkyl substances and (2) bile acids, differed between patient and control groups.Conclusion Our results demonstrate that perfluoroalkyl substances levels are increased in patients with late-onset ulcerative colitis and may contribute to the disease by inducing a dysfunctional intestinal barrier.Competing Interest StatementJ.H. has served as an advisory board member or consultant for Abbvie, Aqilion, Celgene, Celltrion, Ferring, Gil-ead, Janssen, MSD, Novartis, Pfizer, Prometheus Laboratories Inc, Sandoz, Shire, Takeda, Thermo Fisher Scien-tific, Tillotts Pharma, and Vifor Pharma and received grant support from Janssen, MSD and Takeda. All other authors declare that they have no actual or potential competing financial interests. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.Funding StatementThis work was supported by funding from the Faculty of Medicine and Health, Orebro University [grant number: ORU2018/04457 to I.S], Bo Rydin foundation [grant number: F0514 to I.S], Orebro Hospital Research Foundation [Grant number OLL-790011 to J.H] Swedish research council [grant number 2016-05176 to T.H], Formas [grant number. 2019-00869 to T.H and M.O].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Local Ethics Committee approved the study (Dnr: 2006/245), and all patients as well as external controls gave their written informed consent. All animal procedures and protocols were approved by UC Davis animal care and use committee (IACUC #20072).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during the current study are available from the corresponding author on reasonable request.